Overview

Addressing the growing need for innovative and effective treatments for metabolic and endocrine disorders, which affect millions of individuals worldwide, this volume explore the cutting-edge developments in the field, offering a comprehensive overview of emerging therapies that promise to revolutionize patient care. From gene therapy and personalized medicine to advancements in pharmacology and biotechnology, this new book encapsulates the future of treatment modalities that promise to revolutionize patient care. Providing a comprehensive review of emerging therapies, supported by robust scientific evidence and clinical trials, the book delves into the mechanisms of action, potential benefits, and practical applications of these next-gen therapies for metabolic and endocrine disorders, offering healthcare professionals a valuable resource to enhance their practice. Taking a forward-thinking approach, the authors not only discuss the current state of next-gen therapies but also envision future directions and innovations that could further transform the landscape of metabolic and endocrine disorder management. Chapters cover novel therapeutic approaches to metabolic syndromes, such as single-cell transcriptomics, therapeutic approaches to newer classes of drugs and treatments for type 2 diabetes mellitus, the use of artificial intelligence and the internet of things in diagnosis and management of diabetes mellitus, to name a few. The book offers state-of-the-art therapeutic approaches for such health issues as thyroid disorders, type 2 diabetes mellitus, diabetic gastroparesis, high cholesterol, phenylketonuria, cerebrovascular diseases, chronic renal failure, adrenal metabolic disorders, Gaucher disease, Parkinson disease, etc. An essential reference, guiding healthcare professionals towards more effective, personalized, and innovative treatments, this volume will inspire ongoing research and clinical advancements, ultimately leading to improved outcomes and quality of life for patients worldwide.

Full Product Details

9781779640581

Table of Contents

Reviews

“This ground-breaking work represents a significant milestone in our quest to understand and treat metabolic and endocrine disorders more effectively. . . . A comprehensive and forward-thinking resource that delves into the most promising advancements in the field. From gene therapy and stem cell therapy to precision medicine and digital health technologies, this book explores the cutting-edge treatments that are set to redefine how we approach these complex disorders. . . . An invaluable resource, offering up-to-date perspectives on the latest research findings and future directions in the treatment of metabolic and endocrine disorders.” —From the Foreword by Dr. Gaurav Gupta, Adjunct Research Professor, Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates “A remarkable book that stands at the forefront of a rapidly evolving field, offering innovative perspectives and cutting-edge solutions to some of the most challenging metabolic and endocrine disorders of our time. . . . Explore[s] groundbreaking therapies that go beyond conventional approaches, addressing the complexities of these disorders with novel strategies and technologies. . . The authors not only discuss the current state of next-gen therapies but also envision future directions and innovations that could further transform the landscape of metabolic and endocrine disorder management. This holistic perspective is invaluable for clinicians, researchers, and students seeking to stay ahead in a field that is continually evolving. An essential reference, guiding healthcare professionals towards more effective, personalized, and innovative treatments.” —From the Foreword by Dr. Anurag Kuhad, Assistant Professor, University Institute of Pharmaceutical Sciences, Punjab University, India

Author Information

Thakur Gurjeet Singh, PhD, MPharm, has 16 years of experience in industry, research, and teaching. He is working as Dean, Chitkara College of Pharmacy, Chitkara University, Punjab, India. He is engaged with projects on interception of nicotine, morphine, alcohol dependence, ischemia, diabetic neuropathy and nephropathy toxicology, epilepsy, Alzheimer disease, and stem cell research studies and handles affiliation formalities with the director office. He has attended UGC networking courses and various preclinical and clinical research training programs. He has more than 182 research publications (many Scopus-indexed) as well as 25 book chapters, eight books, and 58 filed patents to his name. He has attended more than 60 national and international conferences. He has guided theses for 65 MPharm students and is supervising 10 PhD candidates. He is a reviewer for several international journals. He is a member secretary of the Committee for the Purpose of Control and Supervision of Experiments on Animals and is the In-Charge of the animal house facility at Chitkara College of Pharmacy. He is also a member secretary for institutional human ethical committee registered with the Department of Health Research and CDSCO New Delhi, India. Sanjana Mehta, PhD, is working as an Assistant Professor and the Coordinator of the Institutional Innovation Cell (IIC) at Chitkara College of Pharmacy, Chitkara University, Punjab, India. With five years of academic experience, Dr. Mehta is proficient in clinical studies and medical statistics. Her research interest revolves around advanced pharmacotherapeutic approaches toward metabolic disorders. To date, she has mentored four PharmD students and is currently supervising four PharmD, two MPharm, and one PhD candidate. Dr. Mehta is actively involved in the CancerScreen project, a collaborative venture funded by DST, NewGen IEDC, and Chitkara University, Punjab. Her team has obtained one patent, and she also has a registered copyright to her credit. She has various published patents to her credit. She has also been honored with the Best PhD Award and Award of Honor at the National Pharma Tech & Youth Fest 2023 and 2024. Her academic background includes a PharmD and a PhD in Pharmaceutical Sciences.

Tab Content 6

Countries Available